- IR Sphinx ATR
Chronic Obstructive Pulmonary Disease, or COPD, is a common, progressively disabling disease and a major health burden worldwide. It describes a spectrum of chronic lung diseases that cause limitations in lung airflow, and includes chronic bronchitis and emphysema.
According to WHO estimates, 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD). More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally.
Definitive diagnosis of COPD is not straight-forward and is currently based on accelerated decline in lung function measured using lung function testing. standard. Pistelli et al evaluated the use of spirometry and found elderly patients frequently encountered difficulties due to “fatigue, a lack of co-ordination and cognitive impairment”.
Similarly, Lam et al conducted a systematic literature review evaluating the use of spirometry in COPD screening and diagnosis, finding the use of spirometry alone to be inadequate due to differing guidelines as to what constitutes COPD. There is an urgent need for novel approaches, including tests that can be used at the point of care (POC), are able to diagnose and monitor progression of the disease. Mid-infrared spectroscopy can be used to diagnose and monitoring COPD. Spectrolytics are working exclusively with Glyconics Ltd to develop the Glyconics handheld IR device application for COPD.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.